Jefferies Upgrades Arbutus Biopharma (ABUS) to Buy

Jefferies analyst Dennis Ding upgraded Arbutus Biopharma (NASDAQ: ABUS) from Hold to Buy with a price target of $5.00 (from $4.00).

For an analyst ratings summary and ratings history on Arbutus Biopharma click here. For more ratings news on Arbutus Biopharma click here.

Shares of Arbutus Biopharma closed at $2.92 yesterday.

You May Also Be Interested In

• Several positive 2023 catalysts can boost TransUnion (TRU) valuation - BofA
• Civeo (CVEO) PT Raised to $39 at Stifel
• Dynatrace Inc. (DT) PT Raised to $48 at JPMorgan